| Hans-Günter Meyer-Thompson | Fachveröffentlichungen
Optimal buprenorphine exposure to treat patients with opioid use disorder in the era of fentanyl and polysubstance use.
Optimal buprenorphine exposure to treat patients with opioid use disorder in the era of fentanyl and polysubstance use.
Lohmer LRL, Greenwald MK, Kakar R, Laffont CM.
Front Pharmacol. 2026 Sep 8;17:1839067. doi: 10.3389/fphar.2026.1839067. PMID: 42774285; PMCID: PMC13593607.